Practical guide to immunotherapy in castration resistant prostate cancer: The use of sipuleucel-T immunotherapy

Canadian Journal of Urology

Volumn 21, Issue , 2014, Pages 48-56

  Gomella, Leonard G ^a   Gelpi Hammerschmidt, Francisco ^a   Kundavaram, Chandan ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Castration resistant prostate cancer; Immunotherapy; Sipuleucel T

Indexed keywords

CANCER VACCINE; SIPULEUCEL T; TISSUE EXTRACT;

HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; PRACTICE GUIDELINE; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 84908463338     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29.
2. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-1597.
3. Pezaro C, Omlin A, Lorente D, de Bono J. Management of patients with castration-resistant disease. Hematol Oncol Clin North Am 2013;27(6):1243-1260.
4. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-422.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-674.
6. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 2005;23(32):8262-8269.
7. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013;341(6151):1192-1198.
8. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2(10): 735-747.
9. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S,. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 2007;204(2):345-356.
10. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 2013;Oct 23.
11. Harris DT, Matyas GR, Gomella LG et al Immunologic approaches to the treatment of prostate cancer. Sem in Oncol 1999;26(4):439-447.
12. N elson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004;172(5 Pt 2):S6-S11; discussion S11-S12.
13. Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 2008;179(5 Suppl):S61-S71.
14. Hrouda D, Dalgleish AG. Gene therapy for prostate cancer. Gene Ther 1996;3(10):845-852.
15. Madan RA, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J 2013;19(1):50-58.
16. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004;4(4):575-588.
17. Gomella LG, Mastrangelo MJ, McCue PA et al. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001;166(4):1291-1295.
18. Small EJ, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13(13):3883-3891.
19. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-723.
20. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-2465.
21. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T APC8015 in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-3094.
22. V acchelli E, Vitale I, Eggermont A et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013;2(10):e25771. Epub 2013 Jul 29.
23. N esslinger NJ, Ng A, Tsang KY et al. A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res 2010;16(15):4046-4056.
24. Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011;17(12):3884-3891.
25. Haines AM, Larkin SE, Richardson AP et al. A novel hybridoma antibody PASE/4LJ to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 1989;60(6): 887-892.
26. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002;117(3):471-477.
27. Peshwa MV, Shi JD, Ruegg C et al. Induction of prostate tumorspecific CD8+ cytotoxic T-lymphocytes in vitro using antigenpresenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998;36(2):129-138.
28. Jubinsky PT, Laurie AS, Nathan DG et al. Expression and function of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit. Blood 1994;84(12):4174-4185.
29. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens.Nat Immunol 2004;5(7): 678-684.
30. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115(16):3670-3679.
31. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castrationresistant prostate cancer. J Natl Cancer Inst 2012;104(4): 273-279.
32. Drake CG. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012;104(18):1422, author reply 1422-1423.
33. Gulley JL, Leitman SF, Dahut W, Schlom J. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castrationresistant prostate cancer. J Natl Cancer Inst 2012;104(14):1106, author reply 1109-1112.
34. Gomella LG, Nabhan C, Whitmore JB, Frohlich MW, George DJ. Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase III studies. ASCO 2011 Chicago, IL. J Clin Oncol 2011; 29(suppl):abstract 4534.
35. Schellhammer PF, Chodak G, Whitmore JB et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment IMPACT trial. Urology 2013;81(6):1297-1302.
36. Yu EY, Miller K, Nelson J et al. Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. J Urol 2012;188(1):103-109.
37. Flanigan RC, Polcari AJ, Shore ND et al. An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer. J Urol 2013;189(2):521-526.
38. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10(8):580-593.
39. Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011;17(12):3884-3891.
40. Sheikh NA, Petrylak D, Kantoff PW et al. Sipuleucel-T immune parameters correlate with survival: An analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013;62(1):137-147.
41. Quinn DI, Vaishampayan U, Higano CS et al. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther 2014;14(1):51-61.